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ill patients with Acinetobacter baumannii
bacteremia: Combination is betterFigure 1. Survival curves for critically ill patients with
Acinetobacter baumannii bacteremia (Cox model), adjusted
for age, gender, underlying disease (McCabe classification),
and appropriateness of antimicrobial therapy. Patients
receiving empirical combination therapy were associated with
a lower mortality rate (p Z 0.006).Sir,
Acinetobacter baumannii isolates are resistant to many
drugs and can cause severe infections with high mortality
rates.1 The emergence of A. baumannii isolates with car-
bapenem resistance is a matter of great concern. In the
October 2012 issue, Huang et al2 conducted a retrospective
study to identify the risk factors and outcomes of patients
with carbapenem-resistant A. baumannii (CRAB) bacter-
emia, as compared to carbapenem-susceptible A. bau-
mannii bacteremia. This study demonstrated three
independent factors of 14-day mortality due to CRAB, i.e.,
a high Acute Physiology and Chronic Health Evaluation
(APACHE) score, the presence of shock, and inappropriate
antimicrobial therapy. From Huang’s results, two of these
risk factors were related to disease severity of bacteremia
and were not remediable at the time of diseases onset.
However, early appropriate antimicrobial therapy may be
able to improve the clinical outcome.
Conversely, inappropriate empirical antimicrobial ther-
apy (IEAT) is a potentially modifiable factor, which has
been associated with increased mortality in patients pre-
sented with a critical illness.3 However, the optimal
approach for empirical antibiotic therapy in critical pa-
tients with A. baumannii bacteremia remains controver-
sial. A retrospective cohort study was conducted in a
university hospital. The data from 130 patients with
bacteremia caused by A. baumannii, who presented with
critical illness (defined as a Pitt bacteremia score 4
points) was analyzed. Among this cohort, 27 (20.8%) pa-
tients acquired CRAB bacteremia, 94 (72.3%) individuals
acquired multidrug-resistant bacteremia, and 51 (39.2%)
patients received IEAT. The 30-day crude mortality rate
was statistically higher among patients receiving IEAT than
that of those initially treated by appropriate (in vitro
active) antibiotic regimens (32/63, 50.8% vs. 21/67, 31.3%;1684-1182/$36 Copyright ª 2013, Taiwan Society of Microbiology. Publ
http://dx.doi.org/10.1016/j.jmii.2013.03.004p Z 0.032). Moreover, empirical combination regimens
directed against A. baumannii (i.e., a carbapenem plus
sulbactam or an aminoglycoside) were less likely to be
inappropriate than monotherapy (8/33, 24.2% vs. 44/97,
45.4%; p Z 0.003). A survival analysis of Cox regression
model was applied, after adjusting for age, gender, and
underlying disease (McCabe classification), and found that
patients with empirical combination therapy had a lower
mortality rate (adjusted odds ratioZ 0.31; 95% confidence
interval: 0.15e0.72; p Z 0.006) (Fig. 1).ished by Elsevier Taiwan LLC. All rights reserved.
398 Letter to the EditorExpected benefits of empirical combination therapy for
bacteremia caused by resistant organisms, are based on the
following rationale: to broaden coverage providing at least
one appropriate activity,4 or to exploit the synergy activ-
ity.5 Our study suggests that the use of empirical combi-
nation antimicrobial therapy will be associated with more
appropriateness for patients with critical illness due to A.
baumannii bacteremia and with a favorable outcome.
Therefore, it appears reasonable to initiate empirical
combination antimicrobial therapy directed against A.
baumannii bacteremia in critically ill patients. This
recommendation may be seriously considered for critical
patients at risk of A. baumannii infections, or in the clinical
settings of the presence of endemic multidrug-resistant A.
baumannii in healthcare facilities. However, the optimal
empirical combination regimens directed against A. bau-
mannii infections, should be based on local antimicrobial
susceptibility patterns.
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